Login to Your Account

ASH Roundup

YM Reports Phase I/II Success In Myelofibrosis; Shares Rise

By Catherine Shaffer
BioWorld Today Contributing Writer

Wednesday, December 14, 2011
Stock in YM Biosciences Inc. gained 15.8 percent Tuesday on positive results of a Phase I/II trial of its JAK1/JAK2 inhibitor in myelofibrosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription